Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Commercial Progress
May 12, 2022 07:00 ET | Orchard Therapeutics (Europe) Limited
Product sales for Libmeldy totaled $5.1M for the first two commercial patients treated in Q1 2022 Libmeldy® access and reimbursement expanding with agreements now signed in three major European...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Presentations at ASGCT 2022 Showcasing Potential of HSC Gene Therapy in Neurodegenerative Disorders and Beyond
May 10, 2022 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined seven presentations from across its platform to be featured at...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics to Webcast Conference Call of First Quarter 2022 Financial Results
May 05, 2022 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Agreement Enabling Access and Reimbursement for Libmeldy for All Eligible MLD Patients in Germany
May 02, 2022 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached an agreement with Gesetzliche...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Reimbursement Agreement Making Libmeldy Available for All Eligible MLD Patients in Italy
April 11, 2022 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, April 11, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached another historic reimbursement agreement with...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Extends Runway into 2024, Focusing HSC Gene Therapy Platform Exclusively on Severe Neurometabolic Diseases and Research Platform
March 30, 2022 07:00 ET | Orchard Therapeutics (Europe) Limited
Libmeldy European launch momentum building with multiple MLD patients treated and strong recognition of value proposition; U.S. BLA filing of OTL-200 on track for late 2022 / early 2023 Broad...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics to Webcast Conference Call of Fourth Quarter and Fiscal Year 2021 Financial Results
March 24, 2022 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, March 24, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2022
March 03, 2022 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, March 03, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Multiple Presentations at WORLDSymposium™ 2022
February 07, 2022 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined five upcoming presentations from across its...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Historic Agreement Making Libmeldy Available by NHS England for MLD Patients
February 03, 2022 19:01 ET | Orchard Therapeutics (Europe) Limited
First-ever lentiviral hematopoietic stem cell gene therapy approved for reimbursement by NHS England Two children with early-onset MLD recently treated commercially with Libmeldy in Germany and...